echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Takeda's potential "first-in-class" therapy for NSCLC receives FDA priority review

    Takeda's potential "first-in-class" therapy for NSCLC receives FDA priority review

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Takeda announced that the U.
    S.
    FDA has granted priority review for its new drug application for mobocertinib (TAK-788) for the treatment of metastatic non-small cell lung cancer (NSCLC) with positive EGFR exon 20 insertion.
    Adult patients.
    These patients had previously received platinum-containing chemotherapy.
    The press release states that mobocertinib is the first oral therapy specifically designed to selectively target the insertion of EGFR exon 20.

    Non-small cell lung cancer is the most common type of lung cancer.
    According to statistics from the World Health Organization, it accounts for approximately 85% of newly diagnosed lung cancer cases worldwide each year.
    Metastatic NSCLC patients with positive EGFR exon 20 insertion account for about 1-2% of NSCLC patients, and the disease is more common in Asian populations.
    Such patients have a worse prognosis than other EGFR mutations.
    There is currently no approved targeted therapy for this genetic variant, and existing EGFR tyrosine kinase inhibitors and chemotherapy provide limited benefits for these patients.

    Mobocertinib is a potent oral small molecule tyrosine kinase inhibitor specifically designed to selectively target EGFR exon 20 insertion mutations.
    It was granted a breakthrough therapy designation by the FDA in April 2020 for the treatment of patients with EGFR exon 20 insertion-positive metastatic NSCLC who have progressed during or after platinum-containing chemotherapy.
    In October 2020, mobocertinib was designated as a breakthrough therapy product by the Center for Drug Evaluation (CDE) in China.

    The priority review qualification is awarded based on the results of Phase 1/2 clinical trials.
    The previously published results showed that among 114 patients, according to the evaluation of the independent data monitoring center, mobocertinib reached a confirmed objective remission rate of 28%, with a median remission.
    The duration was 17.
    5 months, and the disease control rate reached 78%.

    ▲Phase 1/2 clinical trial results of Mobocertinib (picture source: reference [2])

    Reference materials:

    [1] Takeda Announces US FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer.
    Retrieved April 27, 2021, from .
    com/news/home/20210427006162/en

    [w] Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy.
    Retrieved January 28, 2021, from

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.